Surgical and oncologic outcomes in surgically treated women 80 years and older with endometrioid endometrial cancer as a function of their comorbidities.
Cancer survival
Comorbidity Index
Mortality
Older women
Postoperative outcomes
Uterine cancer
Journal
Gynecologic oncology reports
ISSN: 2352-5789
Titre abrégé: Gynecol Oncol Rep
Pays: Netherlands
ID NLM: 101652231
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
16
05
2023
revised:
06
07
2023
accepted:
09
07
2023
medline:
28
8
2023
pubmed:
28
8
2023
entrez:
28
8
2023
Statut:
epublish
Résumé
To describe the surgical and oncologic outcomes in surgically treated oldest old women (≥80 years) with endometrioid endometrial cancer as a function of their comorbidities. In this retrospective cohort study, patients aged 80-99 years who underwent surgical management of stage I endometrioid endometrial cancer between 2006 and 2018 were included. Low- and high-intermediate risk disease was defined using the Gynecologic Oncology Group-99 criteria. The validated, Combined Age-Charlson Comorbidity Index (CA-CCI) was used to quantify comorbidity burden. Logistic regression was used to identify the independent predictors of various surgical and oncologic outcomes. Kaplan-Meier survival analysis was performed to compare survival distributions based on mortality cause and comorbidity status. We identified 64 women who met the eligibility criteria. Median age was 84 years (IQR 80, 94 years). Among oldest old women undergoing a hysterectomy with or without lymph node dissection, women with a CA-CCI score of ≥7 had an 8 times higher risk of postoperative infections compared with oldest old women with a <7 score (95% CI 1.53-48.91, Surgical and oncologic outcomes in oldest old women with early stage endometrioid endometrial cancer are largely determined by comorbidity status. Less comorbid women (CA-CCI score < 8) had a significantly higher five-year survival at 87% than their more comorbid counterparts. Use of age-comorbidity risk scoring such as CA-CCI, preoperative optimization, and careful selection for and counseling of patients about surgical treatment are paramount in providing optimal recovery and survival advantages in the oldest old.
Identifiants
pubmed: 37636496
doi: 10.1016/j.gore.2023.101240
pii: S2352-5789(23)00109-1
pmc: PMC10450407
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101240Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors have no conflict of interest to declare.
Références
Menopause. 2010 Jan-Feb;17(1):96-103
pubmed: 19625984
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Am J Obstet Gynecol. 2004 May;190(5):1398-400
pubmed: 15167848
Gynecol Oncol. 2001 Dec;83(3):563-8
pubmed: 11733973
Am J Obstet Gynecol. 2015 Jul;213(1):33.e1-33.e7
pubmed: 25637843
J Physiother. 2016 Jul;62(3):171
pubmed: 27298055
Int J Gynecol Cancer. 2022 Jan;32(1):28-40
pubmed: 34750199
BMC Endocr Disord. 2018 Jun 22;18(1):42
pubmed: 29929558
BMC Surg. 2019 May 28;19(1):54
pubmed: 31138196
Lancet. 2005 Aug 6-12;366(9484):491-505
pubmed: 16084259
J Am Geriatr Soc. 2010 Mar;58(3):527-32
pubmed: 20158557
Am J Obstet Gynecol. 2003 Dec;189(6):1584-7; discussion 1587-9
pubmed: 14710073
Gynecol Oncol. 2016 May;141(2):211-217
pubmed: 26920107
J Arthroplasty. 2019 May;34(5):1013-1024
pubmed: 30745081
Am J Obstet Gynecol. 2018 Jan;218(1):109.e1-109.e11
pubmed: 29037481
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Arch Surg. 2009 Nov;144(11):1013-20
pubmed: 19917937
Medicine (Baltimore). 2018 Jul;97(30):e11703
pubmed: 30045330
Ann Oncol. 2016 Jan;27(1):16-41
pubmed: 26634381
Drugs Aging. 2008;25(5):399-414
pubmed: 18447404
Int J Gynecol Cancer. 2020 Jan;30(1):41-47
pubmed: 31780567
Am J Obstet Gynecol. 2016 Mar;214(3):350.e1-350.e10
pubmed: 26433173
Menopause. 2018 Sep;25(9):968-976
pubmed: 29762198
Am J Obstet Gynecol. 2011 Jul;205(1):66.e1-8
pubmed: 21507372